Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13857484 | 0.83 | CYP2C9 (0.43) | ALDH1A1LMNAMMP1MMP2MMP3 | |
| SCHEMBL13857486 | 0.80 | ALDH1A1 (0.41) | ALDH1A1LMNAMMP1MMP2MMP3 | |
| SCHEMBL18495355 | 0.79 | CTSC (0.33) | CTSCACACBLMNADNM1 | |
| SCHEMBL8468722 | 0.79 | POLB (0.40) | CTSCALDH1A1 | |
| SCHEMBL19686140 | 0.79 | NOD1 (0.35) | CTSCACACBLMNADNM1 | |
| SCHEMBL26838356 | 0.79 | NOD1 (0.35) | CTSCACACBLMNADNM1 | |
| SCHEMBL1133639 | 0.79 | POLB (0.40) | CTSCALDH1A1 | |
| SCHEMBL18771539 | 0.78 | CTSC (0.33) | CTSCACACBALDH1A1 | |
| SCHEMBL25448139 | 0.78 | CTSC (0.34) | CTSC | |
| SCHEMBL19486079 | 0.77 | ALDH1A1 (0.47) | ACACBALDH1A1MMP1MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131306-A1 | CHEMICALLY MODIFIED CYCLIC PEPTIDES CONTAINING CELL ADHESION RECOGNITION (CAR) SEQUENCES AND USES THEREFOR | ADHEREX TECHNOLOGIES, INC. (CA) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131306-A1 | CHEMICALLY MODIFIED CYCLIC PEPTIDES CONTAINING CELL ADHESION RECOGNITION (CAR) SEQUENCES AND USES THEREFOR | VCAM1, EPCAM, ADGRF1 | CTSC 1646/4885ACACB 3714/4885ALDH1A1 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.